1,004
Participants
Start Date
July 31, 2007
Primary Completion Date
May 31, 2008
Study Completion Date
May 31, 2008
OM 40
Initially patients were to be treated with Olmesartanmedoxomil (OM)40 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/12.5 mg and responders remained on the previous therapy for further 8 weeks.
OM/HCTZ 40/12.5
Initially patients were to be treated with Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/25 mg and responders remained on the previous therapy for further 8 weeks.
Rijeka
Slavonski Brod
Split
Varaždin
Zadar
Zagreb
Benátky nad Jizerou
Bílovec
Brodce
Jablonec nad Nisou
Mladá Boleslav
Prague
Rokycany
Tábor
Teplice
Uničov
Aalborg
Ballerup Municipality
Vejle
Berlin
Cologne
Dresden
Einbeck
Essen
Giengen an der Brenz
Großheirath
Hamburg
Hanau
Heidelberg
Künzing
Leipzig
Lollar
Mannheim
München
Nuremberg
Ashkelon
Beersheba
Haifa
Jerusalem
Kfar Saba
Nahariya
Petah Tikva
Tel Aviv
Tel Litwinsky
Busto Arsizio
Ferrara
Pavia
Pisa
San Daniele del Friuli
Sassari
Somma Lombardo
Venezia
Bialystok
Gdansk
Gdynia
Lublin
Płock
Warsaw
Wąbrzeżno
Baia Mare
Brăila
Bucharest
Cluj-Napoca
Oradea
Suceava
Lead Sponsor
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
INDUSTRY
Menarini Group
INDUSTRY